



## Supplementary material

# Interventional Therapies in Pulmonary Hypertension

### SUPPLEMENTARY MATERIAL

**Table 1 of the supplementary material**

Worldwide Experience of Atrial Septostomy for Pulmonary Arterial Hypertension

AUTHOR	PATIENTS LOCATION	PATIENTS (NO.)	PROCEDURES (NO.)	AGE, Y	FEMALE, %	IPAH, %	NYHA/WHO CLASS
NIHILL ET AL. <sup>1</sup>	USA	14	14	20.5 ± 12	78.6	43	3.8 ± 0.4
SOBRINO ET AL. <sup>2</sup>	SPAIN	3	3	36 ± 5	33	67	4.0 ± 0
KERSTEIN ET AL. <sup>3</sup>	USA	15	16	24.9 ± 11.3	87	100	3.53 ± 0.52

THANAPOULOS ET AL. <sup>4</sup>	GREECE	6	6	6.1 ± 2.6	NA	100	3 ± 0
RICH ET AL. <sup>5</sup>	USA	6	6	38.8 ± 7.7	83	100	3.7 ± 0.5
HAYDEN ET AL. <sup>6</sup>	USA	6	6	** 35	83	100	4.0 ± 0
SANDOVAL ET AL. <sup>7</sup>	MEXICO	15	22	33 ± 9	87	87	3.6 ± 0.6
ROTHMAN ET AL. <sup>8</sup>	USA	12	13	37 ± 12	83	75	3.6 ± 0.5
KOTHARI ET AL. <sup>9</sup>	INDIA	11	11	16.2 ± 8.9	36	64	3.62±0.69
REICHENBERGER ET AL. <sup>10</sup>	UK	17	20	35.9 ± 14.2	71	76	3.7 ± 0.5
STÜMPER ET AL. <sup>11</sup>	UK	4	4	63.5 ± 11	NA	100	NA

<b>KURZYNA ET AL.<sup>12</sup></b>	<b>POLAND</b>	<b>2</b>	<b>2</b>	<b>26.5 ± 6.4</b>	<b>100</b>	<b>100</b>	<b>4.0 ± 0</b>
<b>ALLCOCK ET AL.<sup>13</sup></b>	<b>UK</b>	<b>9</b>	<b>12</b>	<b>56.4 ± 22.4</b>	<b>100</b>	<b>67</b>	<b>3.7 ± 0.5</b>
<b>VACHIERY ET AL.<sup>14</sup></b>	<b>BELGIUM</b>	<b>16</b>	<b>18</b>	<b>NA</b>	<b>NA</b>	<b>89</b>	<b>3.6 ± 0.4</b>
<b>MICHELETTI ET AL.<sup>15</sup></b>	<b>UK</b>	<b>20</b>	<b>22</b>	<b>8.4 ± 5.6</b>	<b>55</b>	<b>95</b>	<b>3.5 ± 0.5</b>
<b>KURZYNA ET AL.<sup>16</sup></b>	<b>POLAND</b>	<b>11</b>	<b>14</b>	<b>33.0 ± 12</b>	<b>54.5</b>	<b>82</b>	<b>3.3 ± 0.5</b>
<b>CIARKA ET AL.<sup>17</sup></b>	<b>BELGIUM</b>	<b>11</b>	<b>11</b>	<b>48.0 ± 5</b>	<b>54.5</b>	<b>55</b>	<b>3.5 ± 0.5</b>
<b>LAW ET AL.<sup>18</sup></b>	<b>USA</b>	<b>43</b>	<b>46</b>	<b>** 12.5</b>	<b>81</b>	<b>67</b>	<b>3-4</b>
<b>O'BYRNE ET AL.<sup>19</sup></b>	<b>USA</b>	<b>5</b>	<b>5</b>	<b>29.4 ± 10.5</b>	<b>60</b>	<b>100</b>	<b>3-4</b>

LAMMERS ET AL. <sup>20</sup>	UK	7	7	8.9 ± 5.4	57	100	3.1 ± 0.4
TROOST 2009 ET AL. <sup>21</sup>	BELGIUM	15	17	48.2 ± 20.5	80	33	4.0 ± 0
FENSTAD ET AL. <sup>23</sup>	USA	8	11	40.0 ± 13	89	100	3 - 4
SANDOVAL ET AL. <sup>24</sup>	MEXICO	34	50	35.0 ± 10	85	85	3.5 ± 0.6
BAGLINI ET AL. <sup>25</sup>	ITALY	11	11	42.5 ± 12	54.5	73	3.6 ± 0.5
KUHN ET AL. <sup>26</sup>	USA	16	23	47.6 ± 11.3	75	44	3.8 ± 0.4
CHIU ET AL. <sup>26</sup>	USA	32	46	** 23	74	63	3 - 4
PAN X ET AL. <sup>27</sup>	CHINA	5	5	29 ± 15	40	100	3.6 ± 0.5

<b>VELÁZQUEZ ET AL.<sup>28</sup></b>	<b>SPAIN</b>	<b>10</b>	<b>11</b>	<b>43.5 ± 13.4</b>	<b>80</b>	<b>60</b>	<b>3-4</b>
<b>TOTAL</b>		<b>364</b>	<b>432</b>		<b>68%</b>	<b>76%</b>	<b>3-4</b>

**IPAH, IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; NYHA/WHO, NEW YORK HEART ASSOCIATION/WORLD HEALTH ORGANIZATION. MODIFIED FROM SANDOVAL ET AL.<sup>8</sup> WITH PERMISSION.**

**\*\* MEDIAN.**

**Table 2 of the Supplementary material**

Worldwide Experience of Atrial Septostomy for Pulmonary Arterial Hypertension

Author	Symptoms, %			Procedure (No.)			Reduction in RAP, %	Increase in cardiac index, %	Reduction in SaO <sub>2</sub> %, %	Procedural death, %
	Syncope	RHF	Both	Blade	BDAS	Combined				
Nihill et al. <sup>1</sup>	36	43	21	0	4	10	-2	36	-14	14.2
Sobrinho et al. <sup>2</sup>	0	100	0	0	3	0	-43	53	-36	33
Kerstein et al. <sup>3</sup>	47	0	53	4	0	12	-15	24	-9	16.5
Thanapoulos et al. <sup>4</sup>	50	0	50	0	6	0	-20	39	-12	0
Rich et al. <sup>5</sup>	0	100	0	4	0	2	-41	58	-13	33.3
Hayden et al. <sup>6</sup>	0	17	83	0	6	0	-27	67	-11	33.3
Sandoval et al. <sup>7</sup>	27	53	20	0	22	0	-39	35	-10	4.5
Rothman et al. <sup>8</sup>	50	42	8	0	13	0	-22	24	-9	15.3

Kothari et al. <sup>9</sup>	9	73	18	0	11	0	-16	16	-10	18.1
Reichenberger et al. <sup>10</sup>	24	59	18	0	20	0		29	-6	20
Stümper et al. <sup>11</sup>	NA	NA	NA	0	4	0				0
Kurzyna et al. <sup>12</sup>	0	100	0	0	2	0		19	-12	50
Allcock et al. <sup>13</sup>	100	0	0	0	12	0			-9	5
Vachery et al. <sup>14</sup>	NA	NA	NA	0	18	0			-3	5.5
Micheletti et al. <sup>15</sup>	60	35	5	2	17	3			-8	0
Kurzyna et al. <sup>16</sup>	0	0	100	0	14	0	-5	16	-9	0
Ciarka et al. <sup>17</sup>	9	73	18	0	11	0	-27	27	-8	0
Law et al. <sup>18</sup>	42	51	7	30	5	11	-16	26	-8	4.3
O'Byrne et al. <sup>19</sup>	40	40	20	0	4	1				0
Lammers et al. <sup>20</sup>	43	57	0	0	7	0				0
Troost et al. <sup>21</sup>	0	100	0	0	17	0			-5	5.8
Fenstad et al. <sup>22</sup>	0	100	0	0	11	0				0
Sandoval et al. <sup>23</sup>	26	41	32	0	50	0	-26	31	-8	
Baglini et al. <sup>24</sup>	0	100	0	0	11	0		44	-6	0
Kuhn et al. <sup>25</sup>	31	0	69	0	23	0	2	16	-9	4.3
Chiu et al. <sup>26</sup>	41	46	13	0	46	0	-11	4	-3	0
Pan X et al. <sup>27</sup>	0	100	100	0	5	0	-15	29	-12	0
Velázquez et al. <sup>28</sup>	NA	NA	NA	0	11	0		20	-7	0
<b>Total</b>	<b>25.4</b>	<b>53.2</b>	<b>21.4</b>	<b>42 (9%)</b>	<b>353 (82%)</b>	<b>39 (9%)</b>	<b>-20.1%</b>	<b>30.7%</b>	<b>-9.9%</b>	<b>9.3%</b>

**BDAS, BALLOON DILATION ATRIAL SEPTOSTOMY; RAP, RIGHT ATRIAL PRESSURE; RHF, RIGHT HEART FAILURE; SAO<sub>2</sub>%, ARTERIAL OXYGEN SATURATION.**

**\*MODIFIED FROM SANDOVAL ET AL.<sup>8</sup> WITH PERMISSION.**

### REFERENCES TO THE SUPPLEMENTARY MATERIAL

1. Nihill MR, O'Laughlin MP and Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. *Cathet Cardiovasc Diagn.* 1991;24:166-72.
2. Sobrino N, Frutos A, Calvo L, Casamayor LM, Arcas R. Palliative interatrial septostomy in severe pulmonary hypertension. *Rev Esp Cardiol.* 1993;46:125-128.
3. Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. *Circulation.* 1995; 91: 2028-2035.
4. Thanopoulos BD, Georgakopoulos D, Tsaousis GS, Simeunovic S. Percutaneous balloon dilatation of the atrial septum: immediate and midterm results. *Heart.* 1996;76:502-506.
5. Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. *Am J Cardiol.* 1997;80:369-371.
6. Hayden AM. Balloon atrial septostomy increases cardiac index and may reduce mortality among pulmonary hypertension patients awaiting lung transplantation. *J Transpl Coord.* 1997;7:131-133.
7. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients non-responsive to vasodilator treatment. *J Am Coll Cardiol.* 1998;32:297-304.
8. Rothman A, Slansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. *Am J Cardiol.* 1999;84:682-686.

9. Kothari SS, Yusuf A, Juneja R, et al. Graded balloon atrial septostomy in severe pulmonary hypertension. *Indian Heart J.* 2002;54:164-169.
10. Reichenberger F, Pepke-Zaba J, McNeil K, et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. *Thorax.* 2003;58:797-800.
11. Stümper O, Gewillig M, Vettukattil J, et al. A modified technique of stent fenestration of the atrial septum. *Heart.* 2003;89:1227-1230.
12. Kurzyna M, Dabrowski M, Torbicki A, et al. Atrial septostomy for severe primary pulmonary hypertension. Report of two cases. *Kardiol Pol.* 2003;58:27-33.
13. Allcock RJ, O'Sullivan JJ, Corris PA. Atrial septostomy for pulmonary hypertension. *Heart.* 2003;89:1344-1347.
14. Vachery JL, Stoupe E, Boonstra A, Naeije R. Balloon atrial septostomy for pulmonary hypertension in the prostacyclin era. *Am J Respir Crit Care Med.* 2003;167:A692.
15. Micheletti A, Hislop A, Lammers A, et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. *Heart.* 2006;92:969-972.
16. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. *Chest.* 2007;131:947-948.
17. Ciarka A, Vachery JL, Houssiere A, et al. Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension. *Chest.* 2007; 131: 1831-1837.
18. Law MA, Grifka RG, Mullins CE, Nihill MR. Atrial septostomy improves survival in select patients with pulmonary hypertension. *Am Heart J.* 2007;153:779-784.



19. O'Byrne ML, Berman-Rosenzweig ES, Barst RJ. The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension. *Cardiol Young*. 2007;17:557-559.
20. Lammers AE, Derrick G, Haworth SG, et al. Efficacy and long-term patency of fenestrated amplatzer devices in children. *Catheter Cardiovasc Interv*. 2007;70:578-584.
21. Troost E, Delcroix M, Gewillig M, Van Deyk K, Budts W. A modified technique of stent fenestration of the interatrial septum improves patients with pulmonary hypertension. *Catheter Cardiovasc Interv*. 2009;73:173-179.
22. Fenstad ER, Le RJ, McGoon MD, et al. Atrial Septostomy in Patients with Pulmonary Arterial Hypertension. *Circulation*. 2011;124:A9476.
23. Sandoval J, Gaspar J, Peña H, et al. Effect of Atrial Septostomy on the Survival of Patients with Severe Pulmonary Arterial Hypertension. *Eur Respir Journal*. 2011;38:1343-1348.
24. Baglini R. Atrial septostomy in patients with end-stage pulmonary hypertension. No more needles but wires, energy and close anatomical definition. *J Interv Cardiol*. 2013;26:62-68.
25. Kuhn BT, Javed U, Armstrong EJ, et al. Balloon dilation atrial septostomy for advanced pulmonary hypertension in patients on prostanoid therapy. *Catheter Cardiovasc Interv*. 2015;85:1066-1072.
26. Chiu JS, Zuckerman WA, Turner ME, et al. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes. *J Heart Lung Transplant*. 2015;34:376-380.

27. Pan X, Wang C, Zhang Y, et al. Short-term efficacy of atrial septostomy in the treatment of idiopathic pulmonary arterial hypertension patients complicating with right heart failure. *Zhonghua xin xue Guan Bing za Zhi*. 2015;43:319-322.
28. Velázquez Martín M, Albarrán González-Trevilla A, Jiménez López-Guarch C, García Tejada J, Martín Asenjo R, Escibano Subías P. Use of atrial septostomy to treat severe pulmonary arterial hypertension in adults. *Rev Esp Cardiol*. 2016;69:78-81.